drugset / Trial / NCT07833839
ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, controlled, multicenter Phase III study evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of ZG005 combined with the EP regimen (etoposide plus cisplatin) in participants with advanced NEC who are naive to systemic therapy.
Timeline
- Start
- 2026-10
- Primary completion
- 2031-10
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZG005 | Unknown | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |